Tolvaptan CAS:150683-30-0

CAS NO: 150683-30-0
Chemical Name: N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide
Molecular Formula: C26H25ClN2O3
Formula Weight: 448.94
CAS Number: 150683-30-0
Description Review
Description
An in-depth analysis of Tolvaptan, its chemical properties, benefits, potential effects, mechanism, safety considerations, side effects, dosing information, contraindications, and a conclusion on its therapeutic significance.

Introduction
Tolvaptan is a renowned medication that has garnered attention in the pharmaceutical world due to its unique mechanism of action and therapeutic benefits. It primarily targets the vasopressin receptors, playing a pivotal role in regulating the body's water and salt balance.

Top Ten Keywords from Google
1. Vasopressin V2 receptor antagonist
2. Renoprotective
3. Orally active
4. Arginine vasopressin (AVP) V2-receptor
5. Nonpeptide AVP V2
6. Competitive antagonist
7. IC50 of 1.28 μM
8. Vasopressin Receptor Antagonist
9. Tetrahydro-5-hydroxy
10. Benzazepin-1-yl
Synonyms: OPC-41061
Similar Competitive Products
While Tolvaptan stands out in its class, there are other vasopressin receptor antagonists like Conivaptan and Lixivaptan that are also used for similar indications.
Health Benefits
Tolvaptan is primarily prescribed for the treatment of hyponatremia, especially in patients with conditions like heart failure, cirrhosis, and SIADH. By addressing the imbalance of sodium in the blood, it aids in preventing complications associated with low sodium levels.
Potential Effects
The drug has shown promising results in improving serum sodium levels, reducing the risk of hospitalization in heart failure patients, and potentially slowing the progression of polycystic kidney disease.
Product Mechanism
Tolvaptan acts as a selective antagonist to the vasopressin V2 receptor. By blocking the action of vasopressin on its receptors in the kidneys, it increases water excretion through urine without significantly altering electrolyte levels, thereby raising blood sodium levels.
Safety
While Tolvaptan has proven therapeutic benefits, it's essential to administer it under medical supervision. Regular monitoring, especially during the initial phase of treatment, is crucial to ensure safety.
Side Effects:
Some common side effects include thirst, dry mouth, increased urination, and constipation. There's also a concern regarding potential liver toxicity, making liver function tests vital for patients on this medication.
Dosing Information:
Tolvaptan is administered orally, typically once daily. However, the exact dosage and duration depend on the patient's condition and the treating physician's recommendations.
Contraindication:
Tolvaptan shouldn't be used in patients with anuria, hypovolemic hyponatremia, or those allergic to the drug. Additionally, due to the risk of rapid sodium level correction leading to osmotic demyelination syndrome, it's crucial to monitor patients closely during the initial phase of treatment.
Conclusion:
Tolvaptan, with its unique mechanism and promising therapeutic benefits, offers a ray of hope for patients with hyponatremia and associated conditions. While it's a potent drug, it's essential to use it judiciously, considering its side effects and contraindications. As with any medication, the key lies in personalized treatment, ensuring the drug's benefits outweigh potential risks.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code